Omeros Corporation announced positive sensitivity analysis results for narsoplimab, its monoclonal antibody targeting the lectin pathway of complement, in...

Micron Biomedical secured $16 million in a Series A3 funding round, bringing the total Series A investment to over...

The first patients have been enrolled in the MOSA trial, a pivotal clinical trial evaluating treatments for Mpox (formerly...

Outlook Therapeutics announced positive 12-week results from its NORSE EIGHT trial for ONS-5010, an ophthalmic bevacizumab formulation for wet...

CGT Global, a US-based cell collection and expansion company, and Cellex Cell Professionals, a German cell therapy manufacturer, have...

ImmunityBio announced progress in discussions with the FDA concerning its non-muscle invasive bladder cancer (NMIBC) and non-small cell lung...

Solid Biosciences provided a corporate update highlighting its expanded clinical pipeline and 2025 objectives, focusing on genetic medicines for...

Silexion Therapeutics (NASDAQ: SLXN) announced promising preclinical results for SIL-204, its second-generation siRNA therapy targeting KRAS-mutated cancers. The data...

Radical Catheter Technologies, backed by NeuroTechnology Investors, received FDA 510(k) clearance for its 8F catheter, expanding its neurovascular product...

Brigham and Women’s Hospital has initiated enrollment for the Phase 3 REVEAL study of 124I-evuzamitide (AT-01), a diagnostic imaging...